COMMUNIQUÉS West-GlobeNewswire
-
Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
26/01/2026 -
SciSparc Successfully Completes Acquisition of IP Portfolio, Advances Toward Immediate Commercialization
26/01/2026 -
LB Pharmaceuticals Initiates Phase 2 ILLUMINATE-1 Trial in Bipolar Depression, Expanding LB-102 Development Program
26/01/2026 -
Arcutis Biotherapeutics, Inc. Announces Termination of Promotion Agreement with Kowa
26/01/2026 -
Leios Therapeutics and BNC Korea Announce Strategic Collaboration to Accelerate Development of 10XB-101 in South Korea
26/01/2026 -
Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST)
26/01/2026 -
Primmune Therapeutics Announces Additional Close of Series B Financing
26/01/2026 -
Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)
26/01/2026 -
Genyro Signs Exclusive License for “Sidewinder,” a Breakthrough DNA Construction Technology Featured in Nature
26/01/2026 -
Enlivex Treasury Portfolio Update: Listing of the RAIN Token on WhiteBIT, a Leading Cryptocurrency Exchange
26/01/2026 -
QHSLab (OTCQB:USAQ) Reports Preliminary Unaudited 2025 Financial Results With Strong Revenue Growth, Expanding Margins, and Significant Debt Reduction
26/01/2026 -
Indivior Announces Completion of Redomiciliation to the United States
26/01/2026 -
Good Morning America Features Baylor College of Medicine Pancreatic Cancer Study Utilizing Marker Therapeutics’ MAR-T Cell Technology
26/01/2026 -
Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026
26/01/2026 -
ProPhase Labs Provides Crown Medical Collections Update; 250+ Insurance Payors Engaged, Approximately 50 Matters in Advanced Settlement Posture
26/01/2026 -
Sharps Technology Reports Strong Solana Staking Income
26/01/2026 -
Cannara publie ses résultats pour le premier trimestre de l’exercice 2026, enregistre de nouveaux résultats financiers records, accroît ses parts de marché et poursuit sa stratégie d’expansion disciplinée
26/01/2026 -
Invention of DNA "Page Numbers" Opens Up Vast Possibilities for the Bioeconomy
26/01/2026 -
Coloplast A/S - Q1 2025/26 Earnings Release - Invitation for conference call on 6 Feb 2026 at 11.00am CET
26/01/2026
Pages